Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel D Karp

Showing results (11-20 of 101) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2014
Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung CancerGerald S Falchook, Nelson G Ordóñez, Christel C Bastida, et al.
Investigational New Drugs|March 26, 2021
Pembrolizumab for advanced penile cancer: a case series from a phase II basket trialAndrew W Hahn, Jad Chahoud, Matthew T Campbell, et al.
Journal of Health Care for the Poor and Underserved|February 14, 2022
The CTSA University of Texas Health Science Center (UTHSC) Northeast-Tyler and Rio Grande Valley Success Story: How Rural, Underserved Academic Communities Rapidly Built a Robust Engine for Collaborative COVID-19 Clinical ResearchSteven Idell, David D McPherson, Jessica Martin, et al.
Journal of Oncology Practice|June 23, 2016
Innovative Strategies for Decreasing Blood Collection Wait Times for Patients in Early-Phase Cancer Clinical TrialsBayabel Mengistu, Dina Ray, Passion Lockett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancerCorey J Langer, Silvia Novello, Keunchil Park, et al.
Cancer|May 15, 2009
Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastasesYun Oh, Sarah Taylor, Benjamin Nebiyou Bekele, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 15, 2017
Gene Methylation Biomarkers in Sputum and Plasma as Predictors for Lung Cancer RecurrenceSteven A Belinsky, Shuguang Leng, Guodong Wu, et al.
Cancers|March 10, 2022
Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer CenterHenry Hiep Vo, Carrie Cartwright, I-Wen Song, et al.
Gynecologic Oncology|June 15, 2020
Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tractMichael Frumovitz, Shannon N Westin, Gloria Salvo, et al.
Cancer Chemotherapy and Pharmacology|September 6, 2018
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvementElena Fountzilas, Elangovan Krishnan, Filip Janku, et al.
Pageof 11

Showing results (11-20 of 101) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2014
Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung CancerGerald S Falchook, Nelson G Ordóñez, Christel C Bastida, et al.
Investigational New Drugs|March 26, 2021
Pembrolizumab for advanced penile cancer: a case series from a phase II basket trialAndrew W Hahn, Jad Chahoud, Matthew T Campbell, et al.
Journal of Health Care for the Poor and Underserved|February 14, 2022
The CTSA University of Texas Health Science Center (UTHSC) Northeast-Tyler and Rio Grande Valley Success Story: How Rural, Underserved Academic Communities Rapidly Built a Robust Engine for Collaborative COVID-19 Clinical ResearchSteven Idell, David D McPherson, Jessica Martin, et al.
Journal of Oncology Practice|June 23, 2016
Innovative Strategies for Decreasing Blood Collection Wait Times for Patients in Early-Phase Cancer Clinical TrialsBayabel Mengistu, Dina Ray, Passion Lockett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancerCorey J Langer, Silvia Novello, Keunchil Park, et al.
Cancer|May 15, 2009
Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastasesYun Oh, Sarah Taylor, Benjamin Nebiyou Bekele, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 15, 2017
Gene Methylation Biomarkers in Sputum and Plasma as Predictors for Lung Cancer RecurrenceSteven A Belinsky, Shuguang Leng, Guodong Wu, et al.
Cancers|March 10, 2022
Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer CenterHenry Hiep Vo, Carrie Cartwright, I-Wen Song, et al.
Gynecologic Oncology|June 15, 2020
Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tractMichael Frumovitz, Shannon N Westin, Gloria Salvo, et al.
Cancer Chemotherapy and Pharmacology|September 6, 2018
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvementElena Fountzilas, Elangovan Krishnan, Filip Janku, et al.
Pageof 11